ClinicalTrials.gg
CompletedNCT00372801Updated Oct 16, 2008

Effectiveness Of Single Doses Of Ibuprofen In Patients With Osteoarthritis Of The Knee

A Phase 1 interventional study of Ibuprofen in Osteoarthritis, sponsored by GlaxoSmithKline. Completed at 1 site in Australia. Open to participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2008-10-16.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
Up to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies in Osteoarthritis by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Osteoarthritis · GlaxoSmithKline.

Started
2005
the only one that year
Phase 1
2 of 11
none open now
Registered
2nd of 11
by date

Among the 11 studies in Osteoarthritis by GlaxoSmithKline, this one is the only one that started in 2005, is one of 2 in phase 1, and was the 2nd registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 11 studies in Osteoarthritis by GlaxoSmithKline is open now. The open studies under Osteoarthritis, anywhere →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: Up to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Osteoarthritis by GlaxoSmithKline as a file.
02

Study summary

To demonstrate that new drugs work, many complex multidose studies are often required. The intent of this study is to use Ibuprofen as an example of a marketed pain relief drug to validate a simpler single dose model for future assessment of new pain drugs.

03

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • Osteoarthritis
  • Ibuprofen
  • COX2
  • VAS
  • knee
  • single dose
04

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects diagnosed with primary Osteoarthritis of the knee.
  • Have at least 3 months in symptom duration prior to screening visit.
  • Regular user of a prescribed non-steroidal anti-inflammatory drug (NSAID) or selective cyclo-oxygenase II (COX2) inhibitor for management of knee pain.
  • Pain walking on flat surface within specific interval prior to study start.

Exclusion criteria

Exclusion criteria:

  • History of to NSAIDS.
  • Allergy to Ibuprofen.
  • Use of assistive devices other than a cane or knee brace.
  • History of specified diseases/illnesses.
  • Abnormal blood tests pre-study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
36 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Pain intensity recorded over 0-8 hours using question 1 of the WOMAC (Western Ontario and McMaster University Osteoarthritis Index)pain subscale (visual analog scale).

Secondary outcomes

  1. Responder rate Patient impression of change - 8 & 24 hrs post dose Time to use of rescue medication (paracetamol)

07

Study locations

1 site
  • GSK Investigational Site
    Randwick, Sydney, New South Wales 2031, Australia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 16, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00372801
Lead sponsor
GlaxoSmithKline
First posted
Sep 7, 2006
Start date
Aug 2005
Last update
Oct 16, 2008

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion